Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Short term Debt (2017 - 2025)

Historic Short term Debt for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $2.9 million.

  • Serina Therapeutics' Short term Debt fell 7239.53% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 7239.53%. This contributed to the annual value of $7.6 million for FY2022, which is 708.68% up from last year.
  • Per Serina Therapeutics' latest filing, its Short term Debt stood at $2.9 million for Q3 2025, which was down 7239.53% from $10.5 million recorded in Q3 2024.
  • Over the past 5 years, Serina Therapeutics' Short term Debt peaked at $22.9 million during Q2 2023, and registered a low of $1.5 million during Q3 2023.
  • Moreover, its 5-year median value for Short term Debt was $7.1 million (2021), whereas its average is $8.3 million.
  • Per our database at Business Quant, Serina Therapeutics' Short term Debt crashed by 7909.02% in 2023 and then soared by 58558.32% in 2024.
  • Serina Therapeutics' Short term Debt (Quarter) stood at $7.1 million in 2021, then grew by 7.09% to $7.6 million in 2022, then plummeted by 80.04% to $1.5 million in 2023, then soared by 585.58% to $10.5 million in 2024, then tumbled by 72.4% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $10.5 million for Q3 2024, and $10.4 million during Q2 2024.